Predictive Health Diagnostics Company’s Morningstar Laboratories Receives Clinical Laboratory Permit from Pennsylvania Department of Health

Morningstar to bring much needed laboratory service resources, including COVID-19 antibody testing, to urban and rural communities statewide

Predictive Health Diagnostics Company’s PULS Cardiac Test Plays Key Role in Detecting Vascular Inflammation Common After Receiving COVID-19 Vaccines

PULS Test vascular inflammation biomarkers and scores reveal risk of developing acute coronary syndrome (ACS) which can be increased in mRNA COVID-19 vaccinated patients

Predictive Health Diagnostics Company Expands Smart Science Diagnostics Platform with Acquisition of MUSE Microscopy Inc.

AI-derived imaging platform expands Company’s test development expertise to create next generation diagnostics for pathology

Predictive Health Diagnostics Company Announces Rollout of Proprietary LIS Cloud-Based Laboratory Information System Software

LIS system enables scalable functionality and big data analysis capabilities

Predictive Health Diagnostics Company’s Morningstar Laboratories Reports Expanding In-Network Provider Participation, Achieves Accreditation from College of American Pathologists (CAP)

Expanding in-network status reflects strong demand and utilization of the PULS Cardiac Test™ and DIABETESpredict™ in healthcare settings nationwide

Predictive Health Diagnostics Company Announces Partnership with Madison Core Laboratories for PULS Cardiac Test™ Distribution to 30+ Healthcare Facilities

Distribution targeted to high at-risk co-morbid patient populations

Predictive Health Diagnostics Company Announces Expansion of North American Sales Force

Predictive Health Diagnostics Company expanding sales team to drive market expansion
PULS Cardiac Test™ and DIABETESpredict™ diagnostic tests now being marketed to healthcare providers throughout North America

Predictive Health Diagnostics Company Launches Second Diagnostic Test DIABETESpredict™ in North America

Enters into exclusive distribution agreement with Patia Europe SL, developer of DIABETESpredict.

Predictive Health Diagnostics Company Announces Strong Momentum with 120,000th PULS Cardiac Test™ Order

One-of-a-kind diagnostic blood test identifies asymptomatic at-risk patients missed by the current standard of care.

120,000th PULS Cardiac Test™ Order

One-of-a-kind diagnostic blood test identifies asymptomatic at-risk patients missed by the current standard of care

Predictive Health Diagnostics Company’s Proprietary Computational Technology Enables Development of Specialty Diagnostic Tests to Improve Patient Care

Company announces its business strategy including test development, commercialization, intellectual property, and reimbursement initiatives.

Computational Technology Enables Development

Data-driven technology platform innovates specialty diagnostic tests for diseases with the largest unmet medical needs